Johnson & Johnson HIPS — Percent Change (as a percent) increased by 890.5% to 20.8% in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 617.2%, from 2.9% to 20.8%. This is a positive signal — higher values indicate stronger performance for this metric.
A positive percentage indicates segment expansion, while a negative percentage suggests contraction or loss of market share within the HIPS portfolio.
This metric measures the period-over-period growth rate of revenue for the Health Technology and Innovative Pharmaceutic...
Comparable to organic growth rates or segment revenue growth percentages reported by peer pharmaceutical and medical technology companies.
jnj_segment_hips_percent_change_as_a_percent| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | 19.4% | 222.8% | 16.8% | 31.9% | 28.8% | -3.9% | -6.9% | -1.3% | 20.7% | 21.9% | 14.1% | 2.9% | -9.6% | 2.1% | 20.8% |
| QoQ Change | — | >999% | -92.5% | +89.9% | -9.7% | -113.5% | -76.9% | +81.2% | >999% | +5.8% | -35.6% | -79.4% | -431.0% | +121.9% | +890.5% |
| YoY Change | — | — | — | — | +48.5% | -101.8% | -141.1% | -104.5% | +630.8% | — | >999% | -86.0% | -143.8% | -85.1% | +617.2% |
We use cookies for analytics. See our Privacy and Cookie Policy.